TABLE OF CONTENTS
1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 OVERVIEW OF THE EUROPE TRANSFECTION REAGENTS AND EQUIPMENT MARKET 18
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET APPLICATION COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39
3 EXECUTIVE SUMMARY 40
4 PREMIUM INSIGHT 43
4.1 PESTEL 44
4.2 PORTER'S FIVE FORCES MODEL 45
5 INDUSTRY INSIGHTS: 46
6 EUROPE TRANSFECTION REAGENTS AND EQUIPMENT MARKET, REGULATIONS 47
6.1 EUROPEAN UNION REGULATORY SCENARIO 47
6.2 U.S. REGULATORY SCENARIO 48
6.3 JAPAN REGULATORY SCENARIO 48
6.4 CHINA REGULATORY SCENARIO 49
7 MARKET OVERVIEW 51
7.1 DRIVERS 53
7.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES 53
7.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS 54
7.1.3 GROWING DEMAND FOR CHIMERIC GENES 54
7.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH 55
7.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS 55
7.2 RESTRAINTS 56
7.2.1 HIGH COST OF TRANSFECTION PRODUCTS 56
7.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS 56
7.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE 57
7.3 OPPORTUNITIES 57
7.3.1 EXPLORATION OF EMERGING MARKET 57
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 58
7.3.3 SURGING LEVEL OF INVESTMENT 59
7.4 CHALLENGES 59
7.4.1 LONG APPROVAL PROCEDURE 59
7.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS-ASSOCIATED TRANSFECTION 60
7.4.3 LACK OF TRAINED PROFESSIONALS 61
8 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY PRODUCTS 62
8.1 OVERVIEW 63
8.2 REAGENTS & KITS 66
8.3 INSTRUMENTS 67
9 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY STAGE 69
9.1 OVERVIEW 70
9.2 RESEARCH 73
9.3 PRECLINICAL 73
9.4 CLINICAL PHASES 74
9.5 COMMERCIAL 75
10 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPE 77
10.1 OVERVIEW 78
10.2 TRANSIENT TRANSFECTION REAGENTS AND EQUIPMENT 81
10.3 STABLE TRANSECTION REAGENTS AND EQUIPMENT 81
11 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY METHODS 83
11.1 OVERVIEW 84
11.2 NON-VIRAL METHODS 87
11.3 VIRAL METHODS 87
12 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY TYPES OF MOLECULE 89
12.1 OVERVIEW 90
12.2 PLASMID DNA 92
12.3 SMALL INTERFERING RNA (SIRNA) 93
12.4 PROTEINS 94
12.5 DNA OLIGONUCLEOTIDES 95
12.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS) 96
12.7 OTHERS 96
13 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY ORGANISM 98
13.1 OVERVIEW 99
13.2 MAMMALIAN CELLS 101
13.3 PLANTS 102
13.4 FUNGI 103
13.5 VIRUS 104
13.6 BACTERIA 105
14 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY APPLICATION 106
14.1 OVERVIEW 107
14.2 IN VITRO APPLICATION 109
14.2.1 IN VIVO APPLICATION 111
14.2.2 BIOPRODUCTION 112
14.2.3 OTHERS 112
14.2.4 SYNTHETIC BIOLOGY 113
14.2.5 AGRICULTURE 113
14.2.6 OTHERS 113
15 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY END USER 114
15.1 OVERVIEW 115
15.2 BIOPHARMA 118
15.3 CROS 118
15.4 CMOS/CDMOS 119
15.5 ACADEMIA 120
15.6 HOSPITALS 121
15.7 CLINICAL LABS 122
15.8 OTHERS 123
16 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL 124
16.1 OVERVIEW 125
16.2 DIRECT TENDER 128
16.3 RETAIL SALES 129
16.4 OTHERS 130
17 EUROPE TRANSFECTION REAGENT AND EQUIPMENT MARKET, BY REGION 131
17.1 EUROPE 132
17.1.1 GERMANY 138
17.1.2 U.K. 138
17.1.3 FRANCE 138
17.1.4 ITALY 138
17.1.5 RUSSIA 138
17.1.6 SPAIN 138
17.1.7 TURKEY 138
17.1.8 NETHERLANDS 138
17.1.9 BELGIUM 138
17.1.10 SWITZERLAND 138
17.1.11 REST OF EUROPE 138
18 EUROPE TRANSFECTION REAGENTS AND EQUIPMENT MARKET, COMPANY LANDSCAPE 139
18.1 COMPANY SHARE ANALYSIS: EUROPE 139
19 SWOT ANALYSIS 140
20 COMPANY PROFILE 141
20.1 THERMO FISHER SCIENTIFIC INC. 141
20.1.1 COMPANY SNAPSHOT 141
20.1.2 REVENUE ANALYSIS 141
20.1.3 COMPANY SHARE ANALYSIS 142
20.1.4 PRODUCT PORTFOLIO 142
20.1.5 RECENT DEVELOPMENT 143
20.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 144
20.2.1 COMPANY SNAPSHOT 144
20.2.2 REVENUE ANALYSIS 144
20.2.3 COMPANY SHARE ANALYSIS 145
20.2.4 PRODUCT PORTFOLIO 145
20.2.5 RECENT DEVELOPMENT 146
20.3 PROMEGA CORPORATION 147
20.3.1 COMPANY SNAPSHOT 147
20.3.2 COMPANY SHARE ANALYSIS 147
20.3.3 PRODUCT PORTFOLIO 148
20.3.4 RECENT DEVELOPMENT 148
20.4 TAKARA BIO INC. 149
20.4.1 COMPANY SNAPSHOT 149
20.4.2 REVENUE ANALYSIS 149
20.4.3 COMPANY SHARE ANALYSIS 150
20.4.4 PRODUCT PORTFOLIO 150
20.4.5 RECENT DEVELOPMENT 150
20.5 BIO-RAD LABORATORIES, INC. 151
20.5.1 COMPANY SNAPSHOT 151
20.5.2 REVENUE ANANLYSIS 151
20.5.3 COMPANY SHARE ANALYSIS 152
20.5.4 PRODUCT PORTFOLIO 152
20.5.5 RECENT DEVELOPMENT 153
20.6 ALTOGEN BIOSYSTEMS 154
20.6.1 COMPANY SNAPSHOT 154
20.6.2 PRODUCT PORTFOLIO 154
20.6.3 RECENT DEVELOPMENT 155
20.7 APPLIED BIOLOGICAL MATERIALS INC. (ABM) 156
20.7.1 COMPANY SNAPSHOT 156
20.7.2 PRODUCT PORTFOLIO 156
20.7.3 RECENT DEVELOPMENT 156
20.8 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC) 157
20.8.1 COMPANY SNAPSHOT 157
20.8.2 REVENUE ANALYSIS 157
20.8.3 PRODUCT PORTFOLIO 158
20.8.4 RECENT DEVELOPMENT 158
20.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 159
20.9.1 COMPANY SNAPSHOT 159
20.9.2 PRODUCT PORTFOLIO 159
20.9.3 RECENT DEVELOPMENT 159
20.10 CYTIVA 160
20.10.1 COMPANY SNAPSHOT 160
20.10.2 PRODUCT PORTFOLIO 160
20.10.3 RECENT DEVELOPMENT 160
20.11 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION) 161
20.11.1 COMPANY SNAPSHOT 161
20.11.2 REVENUE ANANLYSIS 161
20.11.3 PRODUCT PORTFOLIO 162
20.11.4 RECENT DEVELOPMENT 162
20.12 GENLANTIS INC. 163
20.12.1 COMPANY SNAPSHOT 163
20.12.2 PRODUCT PORTFOLIO 163
20.12.3 RECENT DEVELOPMENT 163
20.13 GENO TECHNOLOGY INC., USA 164
20.13.1 COMPANY SNAPSHOT 164
20.13.2 PRODUCT PORTFOLIO 164
20.13.3 RECENT DEVELOPMENT 164
20.14 GINKGO BIOWORKS 165
20.14.1 COMPANY SNAPSHOT 165
20.14.2 PRODUCT PORTFOLIO 165
20.14.3 RECENT DEVELOPMENTS 165
20.15 LONZA 166
20.15.1 COMPANY SNAPSHOT 166
20.15.2 REVENUE ANANLYSIS 166
20.15.3 PRODUCT PORTFOLIO 167
20.15.4 RECENT DEVELOPMENT 167
20.16 MAXCYTE, INC. 168
20.16.1 COMPANY SNAPSHOT 168
20.16.2 REVENUE ANALYSIS 168
20.16.3 PRODUCT PORTFOLIO 169
20.16.4 RECENT DEVELOPMENT 169
20.17 MERCK KGAA 170
20.17.1 COMPANY SNAPSHOT 170
20.17.2 REVENUE ANALYSIS 170
20.17.3 PRODUCT PORTFOLIO 171
20.17.4 RECENT DEVELOPMENT 171
20.18 MIRUS BIO LLC. 172
20.18.1 COMPANY SNAPSHOT 172
20.18.2 PRODUCT PORTFOLIO 172
20.18.3 RECENT DEVELOPMENT 172
20.19 ORIGENE TECHNOLOGIES, INC. 174
20.19.1 COMPANY SNAPSHOT 174
20.19.2 PRODUCT PORTFOLIO 174
20.19.3 RECENT DEVELOPMENT 174
20.20 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.) 175
20.20.1 COMPANY SNAPSHOT 175
20.20.2 REVENUE ANALYSIS 175
20.20.3 PRODUCT PORTFOLIO 176
20.20.4 RECENT DEVELOPMENT 176
20.21 POLYPLUS TRANSFECTION 177
20.21.1 COMPANY SNAPSHOT 177
20.21.2 PRODUCT PORTFOLIO 177
20.21.3 RECENT DEVELOPMENT 177
20.22 R&D SYSTEMS, INC. 179
20.22.1 COMPANY SNAPSHOT 179
20.22.2 PRODUCT PORTFOLIO 179
20.22.3 RECENT DEVELOPMENT 179
20.23 SBS GENETECH 180
20.23.1 COMPANY SNAPSHOT 180
20.23.2 PRODUCT PORTFOLIO 180
20.23.3 RECENT DEVELOPMENT 180
20.24 SIGNAGEN LABORATORIES 181
20.24.1 COMPANY SNAPSHOT 181
20.24.2 PRODUCT PORTFOLIO 181
20.24.3 RECENT DEVELOPMENT 181
21 QUESTIONNAIRE 183
22 RELATED REPORTS 188

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.